{
    "Case ID": "067150",
    "Crime_Name": [
        "Patent Infringement"
    ],
    "Crime_Type": [
        "Property Crimes"
    ],
    "Dispute_Type": [
        "Patent infringement dispute"
    ],
    "Legal_Issue": [
        "Whether Novopharm's product infringes claims 1, 41, or 78 of the '852 patent"
    ],
    "Governing_Law": [
        "Purposive construction of patent claims under Canadian patent law"
    ],
    "Procedural_Stage": [
        "Federal Court application"
    ],
    "Evidence_Assessment": [
        "Expert testimonies were analyzed to determine the release profile of Novopharm’s product"
    ],
    "Decision_Outcome": [
        "Application dismissed"
    ],
    "Burden_of_Proof": [
        "On claimant (Janssen-Ortho) to prove infringement"
    ],
    "Credibility_Factor": [
        "Expert evidence evaluated for consistency with prior art and patent specifications"
    ],
    "Legal_Rule": [
        "Patent claims must be interpreted through purposive construction considering the knowledge of a person skilled in the art (PSIA)"
    ],
    "Standard_of_Review": [
        "Objective interpretation of patent claims based on PSIA perspective"
    ],
    "Procedural_Issue": [],
    "Grounds_for_Claim": [
        "Alleged infringement of '852 patent by Novopharm's generic methylphenidate product"
    ],
    "Outcome_on_Merits": [
        "No infringement found"
    ],
    "Decision_Maker": [
        "Federal Court"
    ],
    "Judicial_Review_Outcome": [],
    "Review_Standard": [],
    "Procedural_Fairness_Assessment": [],
    "Key_Evidence_Considered": [
        "Expert testimonies, prior art, drug release profiles, comparison with Ritalin SR"
    ],
    "Legal_Framework": [
        "Canadian Patent Act and jurisprudence on patent claim construction"
    ],
    "Applicant_Challenge": [
        "Janssen-Ortho failed to demonstrate that Novopharm’s product releases methylphenidate in a sustained-ascending dose over time"
    ],
    "Court_Result": [
        "Dismissed"
    ],
    "Legal_Rule_Source": [
        "Case law on purposive construction of patents"
    ],
    "Standard_of_Proof": [
        "Balance of probabilities"
    ],
    "Defendant_Response": [
        "Denial of infringement based on different release mechanism"
    ],
    "Evidence_Type": [
        "Expert evidence, technical data on drug release kinetics"
    ],
    "Remedy_Requested": [
        "Injunction against Novopharm’s product launch"
    ],
    "Outcome": [
        "Novopharm's product found not to infringe the '852 patent"
    ],
    "Decision_Authority": [
        "Federal Court of Canada"
    ],
    "Remedy_Sought": [
        "Exclusion of Novopharm’s generic product from market"
    ],
    "Resolution_Mechanism": [
        "Judicial determination after trial"
    ],
    "Legal_Provision": [
        "Claims 1, 41, and 78 of the '852 patent"
    ],
    "Authority": [
        "Federal Court"
    ],
    "Claimant_Status": [
        "Patent holder (Janssen-Ortho)"
    ],
    "Legal_Provision_Cited": [
        "'852 patent claims"
    ],
    "Grounds_for_Inadmissibility_or_Allegation": [
        "Lack of technical equivalence in release profile"
    ],
    "Applicable_Process": [
        "Patent infringement litigation"
    ],
    "Outcome_of_Review": [],
    "Pending_Relief_or_Application": [],
    "Jurisdiction": [
        "Canada"
    ],
    "Governing_Rule": [
        "Purposive construction rule in patent interpretation"
    ]
}